BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
7/22/2025 9:23:03 AM | Browse: 45 | Download: 175
 |
Received |
|
2025-02-17 07:47 |
|
Peer-Review Started |
|
2025-02-17 07:47 |
|
First Decision by Editorial Office Director |
|
2025-04-03 08:57 |
|
Return for Revision |
|
2025-04-03 08:57 |
|
Revised |
|
2025-04-16 05:07 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2025-06-03 02:55 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2025-06-03 09:49 |
|
Articles in Press |
|
2025-06-03 09:49 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2025-07-09 09:05 |
|
Publish the Manuscript Online |
|
2025-07-22 09:23 |
| ISSN |
2218-4333 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Minireviews |
| Article Title |
Optimizing neoadjuvant chemoradiation in resectable and borderline resectable pancreatic cancer: Evidence-based insights
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Gautam Sarma, Hima Bora and Partha P Medhi |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Hima Bora, Researcher, Department of Radiation Oncology, Tezpur Medical College and Hospital, NH-15, Tezpur 784010, Assam, India. himabora36@gmail.com |
| Key Words |
Adjuvant therapy; Neoadjuvant therapy; Borderline resectable pancreatic cancer; Resectable pancreatic cancer; Pancreatic adenocarcinoma |
| Core Tip |
Recognized from its inception as a systemic disease, localized pancreatic cancer is currently treated with adjuvant chemotherapy and surgical excision to improve survival rates. However, the main obstacle that may postpone or prevent the prompt delivery of adjuvant therapy is the high morbidity and delayed recovery that follows large surgical excision. Thus, acknowledging the potential of neoadjuvant chemoradiation in improving long-term survival and the chance of successful resection for a variety of digestive tract cancers, such as rectal, gastric, and oesophagal cancers, researchers have focused on investigating its potential benefits in the context of both resectable and borderline resectable pancreatic cancer. |
| Publish Date |
2025-07-22 09:23 |
| Citation |
Sarma G, Bora H, Medhi PP. Optimizing neoadjuvant chemoradiation in resectable and borderline resectable pancreatic cancer: Evidence-based insights. World J Clin Oncol 2025; 16(7): 106107 |
| URL |
https://www.wjgnet.com/2218-4333/full/v16/i7/106107.htm |
| DOI |
https://dx.doi.org/10.5306/wjco.v16.i7.106107 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
